Helixgate

Helixgate

Uncategorized

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Published

on

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Published

on

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.​ ​Read More

Continue Reading

Uncategorized

Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

Published

on

Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.

Continue Reading

Uncategorized

Celiac disease is entering a new era of therapeutic innovation

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Published

on

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Continue Reading
Advertisement

Trending